CH679673A5 - - Google Patents
Download PDFInfo
- Publication number
- CH679673A5 CH679673A5 CH3760/89A CH376089A CH679673A5 CH 679673 A5 CH679673 A5 CH 679673A5 CH 3760/89 A CH3760/89 A CH 3760/89A CH 376089 A CH376089 A CH 376089A CH 679673 A5 CH679673 A5 CH 679673A5
- Authority
- CH
- Switzerland
- Prior art keywords
- serum
- mixture
- protease inhibitors
- chromatography
- factors
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract description 35
- 210000002966 serum Anatomy 0.000 claims abstract description 24
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims abstract description 13
- 238000000926 separation method Methods 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 10
- 102000009027 Albumins Human genes 0.000 claims abstract description 7
- 108010088751 Albumins Proteins 0.000 claims abstract description 7
- 239000000872 buffer Substances 0.000 claims description 13
- 229920000936 Agarose Polymers 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000001042 affinity chromatography Methods 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 239000000061 acid fraction Substances 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 239000000985 reactive dye Substances 0.000 claims description 2
- 230000005526 G1 to G0 transition Effects 0.000 claims 1
- 239000012062 aqueous buffer Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003480 eluent Substances 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 238000005227 gel permeation chromatography Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 11
- 238000002955 isolation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 108010067372 Pancreatic elastase Proteins 0.000 description 7
- 102000016387 Pancreatic elastase Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000002753 trypsin inhibitor Substances 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- -1 catepsin G Proteins 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8132—Plasminogen activator inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH3760/89A CH679673A5 (enExample) | 1989-10-16 | 1989-10-16 | |
| DE69009667T DE69009667T2 (de) | 1989-10-16 | 1990-10-10 | Verfahren zur Herstellung von Protease-Inhibitoren. |
| EP90810779A EP0424318B1 (fr) | 1989-10-16 | 1990-10-10 | Procédé de préparation d'inhibiteurs de protéases |
| DK90810779.0T DK0424318T3 (da) | 1989-10-16 | 1990-10-10 | Fremgangsmåde til fremstilling af proteaseinhibitorer |
| AT90810779T ATE106894T1 (de) | 1989-10-16 | 1990-10-10 | Verfahren zur herstellung von protease- inhibitoren. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH3760/89A CH679673A5 (enExample) | 1989-10-16 | 1989-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH679673A5 true CH679673A5 (enExample) | 1992-03-31 |
Family
ID=4262910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH3760/89A CH679673A5 (enExample) | 1989-10-16 | 1989-10-16 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0424318B1 (enExample) |
| AT (1) | ATE106894T1 (enExample) |
| CH (1) | CH679673A5 (enExample) |
| DE (1) | DE69009667T2 (enExample) |
| DK (1) | DK0424318T3 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2271507A (en) * | 1992-09-04 | 1994-04-20 | Summit Technology Ireland Bv | Compositions containing plasmin activity inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983001A (en) * | 1972-05-10 | 1976-09-28 | Ceskoslovenska Akademie Ved | Isolation of biologically active compounds by affinity chromatography |
-
1989
- 1989-10-16 CH CH3760/89A patent/CH679673A5/fr not_active IP Right Cessation
-
1990
- 1990-10-10 DE DE69009667T patent/DE69009667T2/de not_active Expired - Fee Related
- 1990-10-10 AT AT90810779T patent/ATE106894T1/de active
- 1990-10-10 DK DK90810779.0T patent/DK0424318T3/da not_active Application Discontinuation
- 1990-10-10 EP EP90810779A patent/EP0424318B1/fr not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983001A (en) * | 1972-05-10 | 1976-09-28 | Ceskoslovenska Akademie Ved | Isolation of biologically active compounds by affinity chromatography |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE106894T1 (de) | 1994-06-15 |
| DE69009667T2 (de) | 1994-09-29 |
| EP0424318A1 (fr) | 1991-04-24 |
| EP0424318B1 (fr) | 1994-06-08 |
| DK0424318T3 (da) | 1994-06-08 |
| DE69009667D1 (de) | 1994-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2552263B2 (ja) | 抗凝固作用を有する新規ポリペプチド | |
| Feinstein et al. | A rapid method for purification of human granulocyte cationic neutral proteases: purification and characterization of human granulocyte chymotrypsin-like enzyme | |
| Evans et al. | Purification of microsomal signal peptidase as a complex. | |
| CA1341501C (fr) | Vecteurs d'expression et de secretion de l'hirudine par les levures transformees | |
| FR2640142A1 (fr) | Peptide-2 d'activation des neutrophiles | |
| FR2665449A1 (fr) | Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. | |
| EP0179006B1 (fr) | Procédé d'obtention du complexe FVIII/vWF à usage thérapeutique et produits en résultant | |
| EP0402205A1 (fr) | Procédé de préparation de solutions d'albumine purifiée | |
| Teissere et al. | RNA polymerase III from wheat embryos Purification by affinity and hydrophobic chromatographies Characterization and molecular properties | |
| EP0683791B1 (fr) | Composition aqueuse proteinique, glycoproteine contenue, procede d'obtention et utilisations | |
| Hook et al. | Purification and characterization of alpha 1-antichymotrypsin-like protease inhibitor that regulates prohormone thiol protease involved in enkephalin precursor processing. | |
| Six et al. | Purification and properties of two forms of staphylococcal α-toxin | |
| EP0424318B1 (fr) | Procédé de préparation d'inhibiteurs de protéases | |
| CH652932A5 (fr) | Procede pour la preparation d'un concentrat purifie de facteur antihemophile. | |
| Dice et al. | Structural properties of rat serum proteins which correlate with their degradative rates in vivo | |
| CA2378566A1 (fr) | Procede de purification de facteur de stimulation de colonies de granulocytes | |
| EP0383645B1 (fr) | Procédé de fabrication du facteur antihémophilique (FVIIIc) ayant une très haute pureté. | |
| EP1673155B1 (fr) | Procede de dissociation de la molecule d'hemoglobine extracellulaire d'arenicola marina, caracterisation des chaines proteiques constituant ladite molecule et des sequences nucleotidiques codant pour lesdites chaines proteiques | |
| EP0461330A1 (fr) | Fraction inhibitrice de protéases | |
| FR2489838A1 (fr) | Endoproteinase-lys-c provenant de bacteries, sa preparation et son utilisation | |
| DE3115809A1 (de) | Stereospezifische d- und l-asparaginase sowie verfahren zu ihrer herstellung | |
| Kan et al. | Application of aqueous two-phase system in separation/purification of stroma free hemoglobin from animal blood | |
| Dhulster et al. | Advancement in intermediate opioid peptide production in an enzymatic membrane reactor assisted by solvent extraction | |
| FR2590274A1 (fr) | Procede de preparation industrielle d'un extrait de superoxyde dismutase | |
| FR2479834A1 (fr) | Procede de purification des glucosaminoglucanes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |